Immune response and tolerance during chronic hepatitis B virus infection
Antonio Bertoletti
Singapore Institute of Clinical Sciences, A*STAR, Singapore
Search for more papers by this authorAdam Gehring
Singapore Institute of Clinical Sciences, A*STAR, Singapore
Search for more papers by this authorAntonio Bertoletti
Singapore Institute of Clinical Sciences, A*STAR, Singapore
Search for more papers by this authorAdam Gehring
Singapore Institute of Clinical Sciences, A*STAR, Singapore
Search for more papers by this authorAbstract
The hepatitis B virus (HBV) is a hepatotropic non-cytopathic DNA virus that despite the presence of an effective prophylactic vaccine is estimated to infect 300 million people, with a particularly high prevalence in Asia and Africa. It causes liver diseases that vary greatly in severity from person to person. Some subjects control infection efficiently and clear the virus from the bloodstream either without clinically evident liver disease or with an acute inflammation of the liver (acute hepatitis) that can resolve without long-term clinical sequelae. Other patients fail to clear the virus and develop chronic infection. Most chronically infected patients remain asymptomatic without life-threatening liver disease but 10–30% develop liver cirrhosis with possible progression to liver cancer. Outcome of infection and the pathogenesis of liver disease are determined by virus and host factors, which have been difficult tofully elucidate because the host range of HBV is limited to man and chimpanzees. However, the study of animal models of related Hepadnavirus infections and transgenic mouse able to express individual HBV genes or replicate the entire viral genome have clarified several aspects connected to HBV infection. Furthermore, the ability to analyze many immunological phenomena ex vivo through direct quantification of Ag-specific T cells in humans and chimps has considerably increased our knowledge of HBV pathogenesis. Here, we will discuss the distinctions of HBV adaptive immunity between resolved and persistently infected patients and the host/viral factors that can cause and maintain them.
REFERENCES
- 1 Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology 2001; 34: 1225–41.
- 2 Guidotti L, Chisari F. To kill or to cure: options in host defense against viral infection. Curr Opin Immunol 1996; 8: 478–83.
- 3 Grady GF, Lee VA, Prince AM et al. Hepatitis B immune globulin for accidental exposures among medical personnel: final report of a multicenter controlled trial. J Infect Dis 1978; 138: 625–38.
- 4 Ferrari C, Penna A, Bertoletti A et al. Cellular immune response to hepatitis B virus encoded antigens in acute and chronic hepatitis B virus infection. J Immunol 1990; 145: 3442–9.
- 5 Jung M, Spengler U, Schraut W et al. Hepatitis B virus antigen-specific T-cell activation in patients with acute and chronic hepatitis B. J Hepatol 1991; 13: 310–17.
- 6 Penna A, Artini M, Cavalli A et al. Long-lasting memory T cell responses following self-limited acute hepatitis B. J Clin Invest 1996; 98: 1185–94. ISSN: 0021-9738.
- 7 Penna A, Del Prete G, Cavalli A et al. Predominant T-helper 1 cytokine profile of hepatitis B virus nucleocapsid-specific T cells in acute self-limited hepatitis B. Hepatology 1997; 25: 1022–7.
- 8 Rehermann B, Fowler P, Sidney J et al. The cytotoxic T lymphocyte response to multiple hepatitis B virus polymerase epitopes during and after acute viral hepatitis. J Exp Med 1995; 181: 1047–58.
- 9 Penna A, Chisari FV, Bertoletti A et al. Cytotoxic T lymphocytes recognize an HLA-A2-restricted epitope within the hepatitis B virus nucleocapsid antigen. J Exp Med 1991; 174: 1565–70.
- 10 Jung M, Hartmann B, Gerlach J et al. Virus-specific lymphokine production differs quantitatively but not qualitatively in acute and chronic hepatitis B infection. Virology 1999; 261: 165–72.
- 11 Maini MK, Boni C, Ogg GS et al. Direct ex vivo analysis of hepatitis B virus-specific CD8+ T cells associated with the control of infection. Gastroenterology 1999; 117: 1386–96.
- 12 Sobao Y, Tomiyama H, Sugi K et al. The role of hepatitis B virus-specific memory CD8 T cells in the control of viral replication. J Hepatol 2002; 36: 105–15.
- 13 Webster GJ, Reignat S, Brown D et al. Longitudinal analysis of CD8+ T cells specific for structural and nonstructural hepatitis B virus proteins in patients with chronic hepatitis B: implications for immunotherapy. J Virol 2004; 78: 5707–19.
- 14 Chang JJ, Wightman F, Bartholomeusz A et al. Reduced hepatitis B virus (HBV) -specific CD4+ T-cell responses in human immunodeficiency virus type 1-HBV-coinfected individuals receiving HBV-active antiretroviral therapy. J Virol 2005; 79: 3038–51.
- 15 Thimme R, Wieland S, Steiger C et al. CD8 (+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection. J Virol 2003; 77: 68–76.
- 16 Menne S, Roneker CA, Roggendorf M, Gerin JL, Cote PJ, Tennant BC. Deficiencies in the acute-phase cell-mediated immune response to viral antigens are associated with development of chronic woodchuck hepatitis virus infection following neonatal inoculation. J Virol 2002; 76: 1769–80.
- 17 Webster G, Reignat S, Maini M et al. Incubation phase of acute Hepatitis B in man: dynamic of cellular immune mechanism. Hepatology 2000; 32: 1117–24.
- 18 Urbani S, Boni C, Amadei B et al. Acute phase HBV-specific T cell responses associated with HBV persistence after HBV/HCV coinfection. Hepatology 2005; 41: 826–31.
- 19 Thursz M, Thomas H, Greenwood B, Hill A. Heterozygote advantage for HLA-class II type in hepatitis B virus infection. Nat Genet 1997; 17: 11–12.
- 20 Thio CL, Thomas DL, Karacki P et al. Comprehensive analysis of class I and class II HLA antigens and chronic hepatitis B virus infection. J Virol 2003; 77: 12083–7.
- 21 Gallimore A, Dumrese T, Hengartner H, Zinkernagel RM, Rammensee HG. Protective immunity does not correlate with the hierarchy of virus- specific cytotoxic T cell responses to naturally processed peptides. J Exp Med 1998; 187: 1647–57.
- 22 Alberti A, Diana S, Sculard GH, Eddleston AL, Williams R. Detection of a new antibody system reacting with Dane particles in hepatitis B virus infection. Br Med J 1978; 2: 1056–8.
- 23 Wherry EJ, Blattman JN, Murali-Krishna K, Van Der Most R, Ahmed R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J Virol 2003; 77: 4911–27.
- 24 Zhou S, Ou R, Huang L, Price GE, Moskophidis D. Differential tissue-specific regulation of antiviral CD8+ T-cell immune responses during chronic viral infection. J Virol 2004; 78: 3578–600.
- 25 Seeger C, Mason WS. Hepatitis B virus biology. Microbiol Mol Biol Rev 2000; 64: 51–68.
- 26 Milich D, Chen M, Hughes J, Jones J. The secreted Hepatitis B precore antigen can modulate the immune response to the nucleocapsid: a mechanism for persistence. J Immunol 1998; 160: 2013–21.
- 27 Milich D, Jones J, Hughes J, Price J, Raney A, McLachlan A. Is a function of the secreted hepatitis B e antigen to induce immunotolerance in vivo? Proc Natl Acad Sci USA 1990; 87: 6599–603.
- 28 Milich D, Liang TJ. Exploring the biological basis of hepatitis B e antigen in hepatitis B virus infection. Hepatology 2003; 38: 1075–86.
- 29 Chen MT, Billaud JN, Sallberg M et al. A function of the hepatitis B virus precore protein is to regulate the immune response to the core antigen. Proc Natl Acad Sci USA 2004; 101: 14913–18.
- 30 Brunetto M, Giarin M, Oliveri F et al. Wild-type and e antigen-minus hepatitis B viruses and course of chronic hepatitis. Proc Natl Acad Sci USA 1991; 88: 4186–90.
- 31 Banchereau J, Briere F, Caux C et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18: 767–811.
- 32 Lew YY, Michalak TI. In vitro and in vivo infectivity and pathogenicity of the lymphoid cell-derived woodchuck hepatitis virus. J Virol 2001; 75: 1770–82.
- 33 Tavakoli S, Schwerin W, Rohwer A et al. Phenotype and function of monocyte derived dendritic cells in chronic hepatitis B virus infection. J Gen Virol 2004; 85: 2829–36.
- 34 Untergasser A, Zedler U, Langenkamp A. Dendritic cells take up viral antigens but do not support the early steps of hepatitis B virus infection. Hepatology 2006; 43: 539–47.
- 35 Wang FS, Xing LH, Liu MX et al. Dysfunction of peripheral blood dendritic cells from patients with chronic hepatitis B virus infection. World J Gastroenterol 2001; 7: 537–41.
- 36 Beckebaum S, Cicinnati VR, Dworacki G et al. Reduction in the circulating pDC1/pDC2 ratio and impaired function of ex vivo-generated DC1 in chronic hepatitis B infection. Clin Immunol 2002; 104: 138–50.
- 37 Lohr HF, Pingel S, Bocher WO, Bernhard H, Herzog-Hauff S, Rose-John S. Reduced virus specific T helper cell induction by autologous dendritic cells in patients with chronic hepatitis B – restoration by exogenous interleukin-12. Clin Exp Immunol 2002; 130: 107–14.
- 38 Van Der Molen RG, Sprengers D, Binda RS et al. Functional impairment of myeloid and plasmacytoid dendritic cells of patients with chronic hepatitis B. Hepatology 2004; 40: 738–46.
- 39 Akbar SM, Horiike N, Onji M, Hino O. Dendritic cells and chronic hepatitis virus carriers. Intervirology 2001; 44: 199–208.
- 40 Sakaguchi S. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 2000; 101: 455–8.
- 41 Suvas S, Kumaraguru U, Pack CD, Lee S, Rouse BT. CD4+CD25+ T cells regulate virus-specific primary and memory CD8+ T cell responses. J Exp Med 2003; 198: 889–901.
- 42 Maloy KJ, Powrie F. Regulatory T cells in the control of immune pathology. Nat Immunol 2001; 2: 816–22.
- 43 Stoop JN, Van Der Molen RG, Baan CC et al. Regulatory T cells contribute to the impaired immune response in patients with chronic hepatitis B virus infection. Hepatology 2005; 41: 771–8.
- 44 Xu D, Fu J, Jin L et al. Circulating and liver resident CD4+CD25+ regulatory T cells actively influence the antiviral immune response and disease progression in patients with hepatitis B. J Immunol 2006; 177: 739–47.
- 45 Franzese O, Kennedy PT, Gehring AJ et al. Modulation of the CD8+-T-cell response by CD4+ CD25+ regulatory T cells in patients with hepatitis B virus infection. J Virol 2005; 79: 3322–8.
- 46 Accapezzato D, Francavilla V, Paroli M et al. Hepatic expansion of a virus-specific regulatory CD8 (+) T cell population in chronic hepatitis C virus infection. J Clin Invest 2004; 113: 963–72.
- 47 Hyodo N, Nakamura I, Imawari M. Hepatitis B core antigen stimulates interleukin-10 secretion by both T cells and monocytes from peripheral blood of patients with chronic hepatitis B virus infection. Clin Exp Immunol 2004; 135: 462–6.
- 48 Bertolino P, Bowen D, McCaughan G, Fazekas de St. Groth B. Antigen-specific primary activation of CD8+ T cells within the liver. J Immunol 2001; 166: 5430–8.
- 49 Bowen DG, Zen M, Holz L, Davis T, McCaughan GW, Bertolino P. The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity. J Clin Invest 2004; 114: 701–12.
- 50 Bertolino P, Trescol-Biemont M-C, Rabourdin-Combe C. Hepatocytes induce functional activation of naive CD8+ T lymphocytes but fail to promote survival. Eur J Immunol 1998; 28: 221–36.
10.1002/(SICI)1521-4141(199801)28:01<221::AID-IMMU221>3.0.CO;2-F CASPubMedWeb of Science®Google Scholar
- 51 Crispe IN, Dao T, Klugewitz K, Mehal WZ, Metz DP. The liver as a site of T-cell apoptosis: graveyard, or killing field? Immunol Rev 2000; 174: 47–62.
- 52 Isogawa M, Furuichi Y, Chisari FV. Oscillating CD8 (+) T cell effector functions after antigen recognition in the liver. Immunity 2005; 23: 53–63.
- 53 Gehring AJ, Sun D, Kennedy PT et al. The level of viral antigen presented by hepatocytes influences CD8 T-cell function. J Virol 2007; 81: 2940–49.
- 54 Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19: 65–91.
- 55 Kafrouni MI, Brown GR, Thiele DL. Virally infected hepatocytes are resistant to perforin-dependent CTL effector mechanisms. J Immunol 2001; 167: 1566–74.
- 56 Maini MK, Boni C, Lee CK et al. The role of virus-specific CD8+ cells in viral control and liver damage during persistent hepatitis B virus (HBV) infection. J Exp Med 2000; 191: 1269–80.
- 57 Ando K, Moriyama T, Guidotti LG et al. Mechanisms of class I restricted immunopathology. A transgenic mouse model of fulminant hepatitis. J Exp Med 1993; 178: 1541–54.
- 58 Tiegs G, Hentschel J, Wendel A. A T-cell dependent experimental liver injury in mice inducible by concanavallin A. J Clin Invest 1992; 90: 196–203.
- 59 Kusters S, Gantner F, Kunstle G, Tiegs G. Interferon gamma plays a critical role in T cell-dependent liver injury in mice initiated by concanavalin A. Gastroenterology 1996; 111: 462–71.
- 60 Kakimi K, Lane TE, Wieland S et al. Blocking chemokine responsive to gamma-2/interferon (IFN)-gamma inducible protein and monokine induced by IFN-gamma activity in vivo reduces the pathogenetic but not the antiviral potential of hepatitis B virus-specific cytotoxic T lymphocytes. J Exp Med 2001; 194: 1755–66.
- 61 Morita M, Watanabe Y, Akaike T. Protective effect of hepatocyte growth factor on interferon-gamma-induced cytotoxicity in mouse hepatocytes. Hepatology 1995; 21: 1585–93.
- 62 Boni C, Penna A, Bertoletti A et al. Transient restoration of anti-viral T cell responses induced by lamivudine therapy in chronic hepatitis B. J Hepatol 2003; 39: 595–605.
- 63 Rigopoulou EI, Suri D, Chokshi S et al. Lamivudine plus interleukin-12 combination therapy in chronic hepatitis B: antiviral and immunological activity. Hepatology 2005; 42: 1028–36.
- 64 Shimizu Y, Guidotti L, Fowler P, Chisari F. Dendritic cell immunization breaks cytotoxic T lymphocyte tolerance in hepatitis B virus transgenic mice. J Immunol 1998; 161: 4520–6.
- 65 Pol S, Nalpas B, Driss F et al. Efficacy and limitations of a specific immunotherapy in chronic hepatitis B. J Hepatol 2001; 34: 917–21.
- 66 Pancholi P, Lee D, Liu Q et al. DNA prime/canarypox boost-based immunotherapy of chronic hepatitis B virus infection in a chimpanzee. Hepatology 2001; 33: 448–54.
- 67 Heathcote J, McHutchison J, Lee S et al. A pilot study of the CY-1899 T-cell vaccine in subjects chronically infected with hepatitis B virus. The CY1899 T Cell Vaccine Study Group Hepatology 1999; 30: 531–6.
- 68 Mancini-Bourgine M, Fontaine H, Scott-Algara D, Pol S, Brechot C, Michel ML. Induction or expansion of T-cell responses by a hepatitis B DNA vaccine administered to chronic HBV carriers. Hepatology 2004; 40: 874–82.
- 69 Dusheiko G. A pill a day, or two, for hepatitis B? Lancet 1999; 353: 1032–3.
- 70 Akbar SM, Murakami H, Horiike N, Onji M. Dendritic cell-based therapies in the bench and the bedsides. Curr Drug Targets Inflamm Allergy 2004; 3: 305–10.